Advanced in Acute Lymphoblastic Leukemia (ALL)

Joerg A. Krueger

Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Acute Lymphoblastic Leukemia (ALL)
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Joerg Krueger practices in Toronto, Canada. Krueger is rated as an Advanced expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Their top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Hemophagocytic Lymphohistiocytosis, Osteopetrosis, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 55 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 10 articles and participated in 2 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Thal-FabS: Novel Transplant Strategy for High-risk Thalassemia Patients - a Phase I/II Trial of Early Fludarabine Followed by Abatacept and Sirolimus Immunosuppression
Thal-FabS: Novel Transplant Strategy for High-risk Thalassemia Patients - a Phase I/II Trial of Early Fludarabine Followed by Abatacept and Sirolimus Immunosuppression
Enrollment Status: Recruiting
Publish Date: December 19, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Biological, Drug
Study Drugs: KTE-X19 Brexucabtagene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 1/Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
View 2 Less Clinical Trial

55 Total Publications

Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
Journal: Blood advances
Published: January 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Krueger's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile